85 related articles for article (PubMed ID: 12739023)
1. Circulating anti-pericyte autoantibodies are present in Type 2 diabetic patients and are associated with non-proliferative retinopathy.
Nayak RC; Agardh CD; Kwok MG; Stjernquist H; Farthing-Nayak PJ; Agardh E
Diabetologia; 2003 Apr; 46(4):511-3. PubMed ID: 12739023
[TBL] [Abstract][Full Text] [Related]
2. Circulating antipericyte autoantibodies in diabetic retinopathy.
Attawia MA; Nayak RC
Retina; 1999; 19(5):390-400. PubMed ID: 10546933
[TBL] [Abstract][Full Text] [Related]
3. [The role of anti-pericyte antibodies in the development of diabetic retinopathy].
Adamiec J; Oficjalska-Młyńczak J
Klin Oczna; 2005; 107(7-9):541-3. PubMed ID: 16417018
[TBL] [Abstract][Full Text] [Related]
4. Circulating antipericyte autoantibodies: a novel modifier of risk of progression of diabetic retinopathy?
Nayak RC; Lynch K; Gustavsson C; Kwok MG; Farthing-Nayak PJ; Agardh CD; Agardh E
Retina; 2007 Feb; 27(2):211-5. PubMed ID: 17290204
[TBL] [Abstract][Full Text] [Related]
5. Albuminuria and hypertension are independently associated with circulating antipericyte autoantibodies in type 2 diabetic patients.
Nayak RC; Agardh E; Kwok MG; Farthing-Nayak PJ; Lynch K; Agardh CD
Metabolism; 2005 Feb; 54(2):188-93. PubMed ID: 15690312
[TBL] [Abstract][Full Text] [Related]
6. Antibody-mediated retinal pericyte injury: implications for diabetic retinopathy.
Li Y; Smith D; Li Q; Sheibani N; Huang S; Kern T; Nagaraj RH; Lin F
Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5520-6. PubMed ID: 22786897
[TBL] [Abstract][Full Text] [Related]
7. Presence of retinal pericyte-reactive autoantibodies in diabetic retinopathy patients.
Zhang L; Li Y; Payne J; Srivastava S; Fan X; Fung J; Li X; Kern TS; Lin F
Sci Rep; 2016 Feb; 6():20341. PubMed ID: 26839120
[TBL] [Abstract][Full Text] [Related]
8. Plasma metabolic profile reveals PGF2α protecting against non-proliferative diabetic retinopathy in patients with type 2 diabetes.
Peng L; Sun B; Liu M; Huang J; Liu Y; Xie Z; He J; Chen L; Wang D; Zhu Y; Zhang X; Ai D
Biochem Biophys Res Commun; 2018 Feb; 496(4):1276-1283. PubMed ID: 29408756
[TBL] [Abstract][Full Text] [Related]
9. Elevated Levels of Plasma IgA Autoantibodies against Oxidized LDL Found in Proliferative Diabetic Retinopathy but Not in Nonproliferative Retinopathy.
Vavuli S; Salonurmi T; Loukovaara S; Nissinen AE; Savolainen MJ; Liinamaa MJ
J Diabetes Res; 2016; 2016():2614153. PubMed ID: 28090539
[No Abstract] [Full Text] [Related]
10. Circulating markers of inflammation and endothelial function, and their relationship to diabetic retinopathy.
Sasongko MB; Wong TY; Jenkins AJ; Nguyen TT; Shaw JE; Wang JJ
Diabet Med; 2015 May; 32(5):686-91. PubMed ID: 25407692
[TBL] [Abstract][Full Text] [Related]
11. [Impaired antiendotoxin immunity in patients with diabetic retinopathy and type 2 diabetes mellitus].
Zhaboedov GD; Kopaenko AI
Vestn Oftalmol; 2005; 121(6):29-31. PubMed ID: 16405060
[TBL] [Abstract][Full Text] [Related]
12. Development and progression of diabetic retinopathy in patients with Type 1 diabetes who are positive for GAD autoantibody.
Mimura T; Funatsu H; Uchigata Y; Kitano S; Shimizu E; Noma H; Amano S; Araie M; Iwamoto Y; Hori S
Diabet Med; 2004 Jun; 21(6):559-62. PubMed ID: 15154939
[TBL] [Abstract][Full Text] [Related]
13. Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes.
Suguro T; Watanabe T; Kodate S; Xu G; Hirano T; Adachi M; Miyazaki A
Clin Sci (Lond); 2008 Dec; 115(11):327-34. PubMed ID: 18338983
[TBL] [Abstract][Full Text] [Related]
14. Serum autoantibodies against hexokinase 1 manifest secondary to diabetic macular edema onset.
Šimčíková D; Ivančinová J; Veith M; Dusová J; Matušková V; Němčanský J; Kunčický P; Chrapek O; Jirásková N; Gojda J; Heneberg P
Diabetes Res Clin Pract; 2024 Jun; 212():111721. PubMed ID: 38821414
[TBL] [Abstract][Full Text] [Related]
15. Glutamic acid decarboxylase autoantibody prevalence and association with HLA genotype in patients with younger-onset type 1 diabetes and proliferative diabetic retinopathy.
Mimura T; Funatsu H; Uchigata Y; Kitano S; Shimizu E; Amano S; Yamagami S; Noma H; Araie M; Hori S
Ophthalmology; 2005 Nov; 112(11):1904-9. PubMed ID: 16157380
[TBL] [Abstract][Full Text] [Related]
16. Pericyte chemomechanics and the angiogenic switch: insights into the pathogenesis of proliferative diabetic retinopathy?
Durham JT; Dulmovits BM; Cronk SM; Sheets AR; Herman IM
Invest Ophthalmol Vis Sci; 2015 Jun; 56(6):3441-59. PubMed ID: 26030100
[TBL] [Abstract][Full Text] [Related]
17. Pigment epithelium-derived factor is a pericyte mitogen secreted by microvascular endothelial cells: possible participation of angiotensin II-elicited PEDF downregulation in diabetic retinopathy.
Yamagishi S; Matsui T; Nakamura K; Inoue H
Int J Tissue React; 2005; 27(4):197-202. PubMed ID: 16440585
[TBL] [Abstract][Full Text] [Related]
18. Elevated serum levels of N(epsilon)-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema.
Boehm BO; Schilling S; Rosinger S; Lang GE; Lang GK; Kientsch-Engel R; Stahl P
Diabetologia; 2004 Aug; 47(8):1376-9. PubMed ID: 15258735
[TBL] [Abstract][Full Text] [Related]
19. Association of serum N(ε)-Carboxy methyl lysine with severity of diabetic retinopathy.
Mishra N; Saxena S; Shukla RK; Singh V; Meyer CH; Kruzliak P; Khanna VK
J Diabetes Complications; 2016 Apr; 30(3):511-7. PubMed ID: 26782022
[TBL] [Abstract][Full Text] [Related]
20. Five-year incidence and progression of diabetic retinopathy in a defined older population: the Blue Mountains Eye Study.
Cikamatana L; Mitchell P; Rochtchina E; Foran S; Wang JJ
Eye (Lond); 2007 Apr; 21(4):465-71. PubMed ID: 17318200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
